Equities

Haemonetics Corp

Haemonetics Corp

Actions
  • Price (EUR)76.00
  • Today's Change2.00 / 2.70%
  • Shares traded0.00
  • 1 Year change+5.56%
  • Beta--
Data delayed at least 15 minutes, as of Mar 27 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Its segments include Plasma, Blood Center, and Hospital. Its Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to collect and separate blood components for transfusions. Its Hospital segment provides patient care and has four product lines: hemostasis management, vascular closure, cell salvage, and transfusion management. Its portfolio also includes fiber optic sensor technology in the interventional cardiology market.

  • Revenue in USD (TTM)1.27bn
  • Net income in USD126.57m
  • Incorporated1985
  • Employees3.03k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
HAE:NYQ since
announced
Transaction
value
Advanced Cooling Therapy IncAnnounced05 Mar 202405 Mar 2024Announced14.13%160.00m
Opsens IncDeal completed10 Oct 202310 Oct 2023Deal completed-5.95%245.87m
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.